Meloxicam SBEβCD Inclusion Complex for Rapid Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief, which can be improved by forming an inclusion complex with cyclodextrins like sulfobutyl ether β-cyclodextrin (SBEβCD) and using bicarbonate to enhance solubility and absorption.
Innovation Solution
The combination of meloxicam with SBEβCD and bicarbonate forms an inclusion complex that increases the solubility and bioavailability of meloxicam, allowing for rapid and sustained pain relief when administered orally or intravenously, often in conjunction with rizatriptan for treating migraines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If meloxicam is administered alone, then the drug can be given in a simple formulation, but the aqueous solubility is poor leading to reduced bioavailability
Solution Approach 1:
The patent uses cyclodextrins as intermediary carrier molecules that form inclusion complexes with meloxicam. The cyclodextrin's hydrophobic cavity accommodates the meloxicam molecule while the hydrophilic exterior enhances aqueous solubility, acting as a mediator between the poorly soluble drug and the aqueous environment for improved bioavailability without overly complicating the formulation
2Device complexity
If meloxicam is administered alone, then the formulation is simple, but the onset of pain relief is slow
Solution Approach 1:
The patent changes the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This alters the dissolution rate and absorption characteristics of the drug, enabling faster onset of pain relief while maintaining formulation simplicity through the use of well-established cyclodextrin carriers
3Reliability
If cyclodextrins are used to increase solubility, then bioavailability improves, but the formulation becomes more complex
Solution Approach 1:
The patent employs cyclodextrins that serve multiple functions simultaneously: they act as solubility-enhancing carriers, provide controlled release properties, and can be administered in various routes (oral, intravenous, intramuscular). This multi-functionality justifies the increased formulation complexity by delivering multiple benefits from a single carrier system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination provides rapid and sustained pain relief, significantly reducing the need for rescue medication and improving outcomes in patients with inadequate responses to prior treatments, with enhanced bioavailability and absorption rates compared to meloxicam alone.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Cyclodextrins are hydrophobic on the inside and hydrophilic on the inside which helps to facilitate the transport of molecules
Implementation Method 3
using bicarbonate to enhance solubility and absorption
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.